Heparin-Based Anticoagulation Strategies in Sepsis-Associated Coagulopathy: A Systematic Review
DOI:
https://doi.org/10.5281/zenodo.22644214Keywords:
sepsis-induced coagulopathy, disseminated intravascular coagulation, unfractionated heparin, low molecular weight heparin, anticoagulant therapy in sepsisAbstract
Background: Sepsis-induced coagulopathy (SIC) and disseminated intravascular coagulation (DIC) are core drivers of organ failure
and death in sepsis, and heparins occupy a distinctive therapeutic niche by combining antithrombin-potentiated anticoagulation
with antithrombin-independent anti-inflammatory and glycocalyx-protective actions. Objective: To systematically synthesize the
clinical evidence for unfractionated heparin (UFH) and low molecular weight heparin (LMWH) in sepsis-associated coagulopathy
and to compare this evidence against the natural-anticoagulant replacement trials (antithrombin, tissue factor pathway inhibitor,
and thrombomodulin) tested in severe sepsis. Methods: A narrative systematic review was conducted of randomized controlled
trials, meta-analyses, and coagulopathy-stratified cohort studies of heparin therapy in adult sepsis and sepsis-associated DIC, with
all sources independently verified against original publications. Findings: The largest unselected randomized trial of
unfractionated heparin (HETRASE, n=305) found no significant 28-day mortality benefit, whereas coagulopathy-enriched
propensity-matched cohorts and observational studies restricted to patients with sepsis-induced coagulopathy scores consistently
reported reduced mortality, particularly with early initiation and moderate cumulative dosing. Five meta-analyses of randomized
trials pooling low molecular weight and unfractionated heparin reported mortality risk or odds ratios ranging from 0.52 to 0.86,
generally favoring heparin, although the associated bleeding-risk signal varied from significantly increased to significantly
decreased across analyses. In contrast, three large phase III trials of single-target natural-anticoagulant replacement
(antithrombin, tissue factor pathway inhibitor, and recombinant thrombomodulin) in unselected or coagulopathy-enriched severe
sepsis populations each failed to demonstrate a significant mortality benefit, though coagulopathy-severity-stratified subgroup
analyses of these same trials revealed benefit signals analogous to those seen with heparin. Conclusions: Heparin-based
anticoagulation shows a mechanistically coherent and increasingly consistent, though not yet definitively proven, mortality benefit
in sepsis-associated coagulopathy, particularly when restricted to coagulopathy-enriched populations, and this
coagulopathy-stratified approach should guide the design of future confirmatory randomized trials.
References
Shankar-Hari M, Phillips GS, Levy ML, Seymour CW, Liu VX, Deutschman CS, Angus DC, Rubenfeld GD, Singer M (2016) Developing a New Definition and Assessing New Clinical Criteria for Septic Shock: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA, 315(8):775-787, DOI:10.1001/jama.2016.0289.
Seymour CW, Liu VX, Iwashyna TJ, Brunkhorst FM, Rea TD, Scherag A, Rubenfeld G, Kahn JM, Shankar-Hari M, Singer M, Deutschman CS, Escobar GJ, Angus DC (2016) Assessment of Clinical Criteria for Sepsis: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA, 315(8):762-774, DOI:10.1001/jama.2016.0288.
Levi M, van der Poll T (2017) Coagulation and sepsis. Thrombosis Research, 149:38-44, DOI:10.1016/j.thromres.2016.11.007.
Iba T, Levy JH, Warkentin TE, Thachil J, van der Poll T, Levi M (2019) Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis, 17(11):1989-1994, DOI:10.1111/jth.14578.
Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Penzes I, Kubler A, Knaub S, Keinecke HO, Heinrichs H, Schindel F, Juers M, Bone RC, Opal SM (2001) High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA, 286(15):1869-1878, DOI:10.1001/jama.286.15.1869.
Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Lopez Rodriguez A, Beale R, Svoboda P, Laterre PF, Simon S, Light B, Spapen H, Stone J, Seibert A, Peckelsen C, De Deyne C, Postier R, Pettila V, Sprung CL, Artigas A, Percell SR, Shu V, Zwingelstein C, Tobias J, Poole L, Stolzenbach JC, Creasey AA (2003) Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA, 290(2):238-247, DOI:10.1001/jama.290.2.238.
Vincent JL, Francois B, Zabolotskikh I, Daga MK, Lascarrou JB, Kirov MY, Pettila V, Wittebole X, Meziani F, Mercier E, Lobo SM, Barie PS, Crowther M, Esmon CT, Fareed J, Gando S, Gorelick KJ, Levi M, Mira JP, Opal SM, Parrillo J, Russell JA, Saito H, Tsuruta K, Sakai T, Fineberg D (2019) Effect of a recombinant human soluble thrombomodulin on mortality in patients with sepsis-associated coagulopathy: the SCARLET randomized clinical trial. JAMA, 321(20):1993-2002, DOI:10.1001/jama.2019.5358.
Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M (2001) Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thrombosis and Haemostasis, 86(5):1327-1330.
Zhang H, Sun Y, An X, Ma X (2021) Unfractionated heparin improves the intestinal microcirculation in a canine septic shock model. Mediators of Inflammation, 2021:9985397, DOI:10.1155/2021/9985397.
Jaimes F, De La Rosa G, Morales C, Fortich F, Arango C, Aguirre D, Munoz A (2009) Unfractioned heparin for treatment of sepsis: a randomized clinical trial (the HETRASE Study). Critical Care Medicine, 37(4):1185-1196, DOI:10.1097/CCM.0b013e31819c06bc.
Zarychanski R, Doucette S, Fergusson D, Roberts D, Houston DS, Sharma S, Gulati H, Kumar A (2008) Early intravenous unfractionated heparin and mortality in septic shock. Critical Care Medicine, 36(11):2973-2979, DOI:10.1097/CCM.0b013e31818b8c6b.
Huang JJ, Zou ZY, Zhou ZP, Liu Y, Yang ZJ, Zhang JJ, Luan YY, Yao YM, Wu M (2023) Effectiveness of early heparin therapy on outcomes in critically ill patients with sepsis-induced coagulopathy. Frontiers in Pharmacology, 14:1173893, DOI:10.3389/fphar.2023.1173893.
Ushio N, Yamakawa K, Mochizuki K, Hisamune R, Umemura Y, Takasu A (2024) Efficacy of unfractionated heparin in patients with moderate sepsis-induced coagulopathy: an observational study. Thrombosis Research, 241:109095, DOI:10.1016/j.thromres.2024.109095.
Ren ZF, Huang JJ, Xin K, Yang ZJ, Li DZ, Chen YH, Guan YH, Liu ZF, Wu M (2025) Heparin therapy was associated with the reduction of ICU mortality in geriatric patients with sepsis: a retrospective cohort study. Clinical and Applied Thrombosis/Hemostasis, 31:10760296251386049, DOI:10.1177/10760296251386049.
Sun Q, Wang S, Ding X, Sun T, Wang B, Shao T, Yu Z, Han Y (2025) The impact of continuous intravenous administration of heparin on coagulation dysfunction and organ failure in patients with sepsis. Scientific Reports, 15:38781, DOI:10.1038/s41598-025-22773-x.
Wang C, Chi C, Guo L, Wang X, Guo L, Sun J, Sun B, Liu S, Chang X, Li E (2014) Heparin therapy reduces 28-day mortality in adult severe sepsis patients: a systematic review and meta-analysis. Critical Care, 18:563, DOI:10.1186/s13054-014-0563-4.
Fan Y, Jiang M, Gong D, Zou C (2016) Efficacy and safety of low-molecular-weight heparin in patients with sepsis: a meta-analysis of randomized controlled trials. Scientific Reports, 6:25984, DOI:10.1038/srep25984.
Li X, Liu Z, Luo M, Xi Y, Li C, Wang S, Yang R (2021) Therapeutic effect of low-molecular-weight heparin on adult sepsis: a meta-analysis. Annals of Palliative Medicine, 10(3):3115-3127, DOI:10.21037/apm-21-169.
Fu S, Yu S, Wang L, Ma X, Li X (2022) Unfractionated heparin improves the clinical efficacy in adult sepsis patients: a systematic review and meta-analysis. BMC Anesthesiology, 22:28, DOI:10.1186/s12871-021-01545-w.
Totoki T, Koami H, Makino Y, Wada T, Ito T, Yamakawa K, Iba T (2024) Heparin therapy in sepsis and sepsis-associated disseminated intravascular coagulation: a systematic review and meta-analysis. Thrombosis Journal, 22:84, DOI:10.1186/s12959-024-00653-0.
van der Poll T (2019) Recombinant human soluble thrombomodulin in patients with sepsis-associated coagulopathy: another negative sepsis trial? JAMA, 321(20):1978-1980, DOI:10.1001/jama.2019.5792.
Yamakawa K, Levy JH, Iba T (2019) Recombinant human soluble thrombomodulin in patients with sepsis-associated coagulopathy (SCARLET): an updated meta-analysis. Critical Care, 23:302, DOI:10.1186/s13054-019-2587-2.
Sun Y, Ding R, Sun H, Liang Y, Ma X (2024) Efficacy and safety of heparin for sepsis-induced disseminated intravascular coagulation (HepSIC): study protocol for a multicenter randomized controlled trial. Trials, 25:4, DOI:10.1186/s13063-023-07853-5.
